156 related articles for article (PubMed ID: 38646521)
21. Ex vivo-expanded NK cells from blood and ascites of ovarian cancer patients are cytotoxic against autologous primary ovarian cancer cells.
Nham T; Poznanski SM; Fan IY; Shenouda MM; Chew MV; Lee AJ; Vahedi F; Karimi Y; Butcher M; Lee DA; Hirte H; Ashkar AA
Cancer Immunol Immunother; 2018 Apr; 67(4):575-587. PubMed ID: 29299659
[TBL] [Abstract][Full Text] [Related]
22. The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells.
Fischer L; Penack O; Gentilini C; Nogai A; Muessig A; Thiel E; Uharek L
Exp Hematol; 2006 Jun; 34(6):753-9. PubMed ID: 16728280
[TBL] [Abstract][Full Text] [Related]
23. Hepatitis C virus-induced NK cell activation causes metzincin-mediated CD16 cleavage and impaired antibody-dependent cytotoxicity.
Oliviero B; Mantovani S; Varchetta S; Mele D; Grossi G; Ludovisi S; Nuti E; Rossello A; Mondelli MU
J Hepatol; 2017 Jun; 66(6):1130-1137. PubMed ID: 28192188
[TBL] [Abstract][Full Text] [Related]
24. TGF-β signalling limits effector function capacity of NK cell anti-tumour immunity in human bladder cancer.
Wong JKM; McCulloch TR; Alim L; Omer N; Mehdi AM; Tuong ZK; Bonfim-Melo A; Chung E; Nicol A; Simpson F; Rhee H; Rossi GR; Souza-Fonseca-Guimaraes F
EBioMedicine; 2024 Jun; 104():105176. PubMed ID: 38810560
[TBL] [Abstract][Full Text] [Related]
25. NK cell dysfunction with down-regulated CD16 and up-regulated CD56 molecules in patients with esophageal squamous cell carcinoma.
Watanabe M; Kono K; Kawaguchi Y; Mizukami Y; Mimura K; Maruyama T; Izawa S; Fujii H
Dis Esophagus; 2010 Nov; 23(8):675-81. PubMed ID: 20545975
[TBL] [Abstract][Full Text] [Related]
26. NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement.
Wang SY; Racila E; Taylor RP; Weiner GJ
Blood; 2008 Feb; 111(3):1456-63. PubMed ID: 18024795
[TBL] [Abstract][Full Text] [Related]
27. Reactivity of NK Cells Against Ovarian Cancer Cells Is Maintained in the Presence of Calcium Phosphate Nanoparticles.
Hrvat A; Schmidt M; Obholzer M; Benders S; Kollenda S; Horn PA; Epple M; Brandau S; Mallmann-Gottschalk N
Front Immunol; 2022; 13():830938. PubMed ID: 35251021
[TBL] [Abstract][Full Text] [Related]
28. [Detection of lymphocyte subsets in the peripheral blood of patients with malignant ovarian tumors].
Liu M; Xie J; Zhao S
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jun; 30(6):627-9, 634. PubMed ID: 24909286
[TBL] [Abstract][Full Text] [Related]
29. FcgammaRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck.
Taylor RJ; Chan SL; Wood A; Voskens CJ; Wolf JS; Lin W; Chapoval A; Schulze DH; Tian G; Strome SE
Cancer Immunol Immunother; 2009 Jul; 58(7):997-1006. PubMed ID: 18979096
[TBL] [Abstract][Full Text] [Related]
30. The human natural killer cytotoxic cell line NK-92, once armed with a murine CD16 receptor, represents a convenient cellular tool for the screening of mouse mAbs according to their ADCC potential.
Clémenceau B; Vivien R; Pellat C; Foss M; Thibault G; Vié H
MAbs; 2013; 5(4):587-94. PubMed ID: 23770975
[TBL] [Abstract][Full Text] [Related]
31. Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines.
Park JE; Kim SE; Keam B; Park HR; Kim S; Kim M; Kim TM; Doh J; Kim DW; Heo DS
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32830112
[TBL] [Abstract][Full Text] [Related]
32. IL-15 and IL-2 increase Cetuximab-mediated cellular cytotoxicity against triple negative breast cancer cell lines expressing EGFR.
Roberti MP; Barrio MM; Bravo AI; Rocca YS; Arriaga JM; Bianchini M; Mordoh J; Levy EM
Breast Cancer Res Treat; 2011 Nov; 130(2):465-75. PubMed ID: 21308409
[TBL] [Abstract][Full Text] [Related]
33. Anti-EGFR antibody cetuximab enhances the cytolytic activity of natural killer cells toward osteosarcoma.
Pahl JH; Ruslan SE; Buddingh EP; Santos SJ; Szuhai K; Serra M; Gelderblom H; Hogendoorn PC; Egeler RM; Schilham MW; Lankester AC
Clin Cancer Res; 2012 Jan; 18(2):432-41. PubMed ID: 22090361
[TBL] [Abstract][Full Text] [Related]
34. Rapid degranulation of NK cells following activation by HIV-specific antibodies.
Chung AW; Rollman E; Center RJ; Kent SJ; Stratov I
J Immunol; 2009 Jan; 182(2):1202-10. PubMed ID: 19124764
[TBL] [Abstract][Full Text] [Related]
35. Agonistic effects of anti-CD2 and anti-CD16 antibodies on human natural killer killing.
Uggla CK; Geisberg M; Jondal M; Knowles RW
Scand J Immunol; 1989 May; 29(5):507-15. PubMed ID: 2567053
[TBL] [Abstract][Full Text] [Related]
36. Rapid and potent induction of cell death and loss of NK cell cytotoxicity against oral tumors by F(ab')2 fragment of anti-CD16 antibody.
Jewett A; Teruel A; Romero M; Head C; Cacalano N
Cancer Immunol Immunother; 2008 Jul; 57(7):1053-66. PubMed ID: 18188563
[TBL] [Abstract][Full Text] [Related]
37. Characterization of FcγRIIIA effector cells used in in vitro ADCC bioassay: Comparison of primary NK cells with engineered NK-92 and Jurkat T cells.
Hsieh YT; Aggarwal P; Cirelli D; Gu L; Surowy T; Mozier NM
J Immunol Methods; 2017 Feb; 441():56-66. PubMed ID: 27939300
[TBL] [Abstract][Full Text] [Related]
38. Tribody [(HER2)
Oberg HH; Kellner C; Gonnermann D; Sebens S; Bauerschlag D; Gramatzki M; Kabelitz D; Peipp M; Wesch D
Front Immunol; 2018; 9():814. PubMed ID: 29725336
[TBL] [Abstract][Full Text] [Related]
39. Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D.
Sayitoglu EC; Georgoudaki AM; Chrobok M; Ozkazanc D; Josey BJ; Arif M; Kusser K; Hartman M; Chinn TM; Potens R; Pamukcu C; Krueger R; Zhang C; Mardinoglu A; Alici E; Temple HT; Sutlu T; Duru AD
Front Immunol; 2020; 11():40. PubMed ID: 32082316
[TBL] [Abstract][Full Text] [Related]
40. Antibody Afucosylation Augments CD16-Mediated Serial Killing and IFNγ Secretion by Human Natural Killer Cells.
Karampatzakis A; Brož P; Rey C; Önfelt B; Cruz De Matos GDS; Rycroft D; Ambrose A; Davis DM
Front Immunol; 2021; 12():641521. PubMed ID: 33796107
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
